Early immune markers of clinical, virological, and immunological outcomes in patients with COVID-19: a multi-omics study.

Submitted by hipc_admin on
PMID
36239699
authors
Hu, Z et al
abstract
Support for the study was provided from National Institute of Health/National Institute of Allergy and Infectious Diseases (NIH/NIAID) (U01 AI150741-01S1 and T32-AI052073), the Stanford's Innovative Medicines Accelerator, National Institutes of Health/National Institute on Drug Abuse (NIH/NIDA) DP1DA046089, and anonymous donors to Stanford University. Peginterferon lambda provided by Eiger BioPharmaceuticals.
status
available
journal
eLife
manuscript url
https://pubmed.ncbi.nlm.nih.gov/36239699/
year of publication
2022
In Dashboard
No